Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors

• Pei Pei Chong,
• Joshua B. Rubin,
• Maha Abdullah,
• Fabio Conforti,
• Sabra L. Klein,
• Wanli Liu,
• Wanli Liu

Affiliations

Pei Pei Chong

School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia

Joshua B. Rubin

School of Medicine, Washington University at St. Louis, St. Louis, MO, United States

Maha Abdullah

Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia

Fabio Conforti

Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology (IEO), Milan, Italy

Sabra L. Klein

W Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, United States

Wanli Liu

School of Life Sciences, Institute for Immunology, Ministry of Education (MOE) Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, China

Wanli Liu

Tsinghua-Peking Center for Life Sciences, Beijing, China